Bigger isn’t always better in the medical world. Indeed often miniaturisation, clever point-of-care diagnostics, lower costs, faster treatment and freeing hospital capacity is far more important than raw power alone. That’s the opportunity for Adaptix Ltd’s low-dose 3D X-ray technology – offering cheaper, super accurate & FDA approved imaging to local healthcare clinics and doctors’ surgeries.

Today, Adaptix Ltd (Avingtrans  subsidiary) has added another potentially valuable string to its bow - signing a memorandum of understanding with IBEX Innovations to integrate its CorteX bone-health software into the Ortho350 imaging platform.

The attraction? Patients could receive a pay-per-scan bone-density report alongside routine assessments, helping clinicians identify bone loss and elevated fracture risk earlier. Particularly relevant for the elderly &/or women approaching menopause, who might otherwise discover a problem only after breaking a bone.

CorteX produces the same recognised clinical biomarkers as DXA bone-density testing. Combining that capability with Adaptix’s portable scanner could make assessment more accessible, while strengthening the commercial case for clinics to buy an Ortho350.

What's more, each scan potentially brings recurring income alongside equipment sales. Preliminary surveys suggest strong patient willingness to pay, although pricing, revenue-sharing and financial contributions are yet to be decided. It’s worth nothing too that this is an initial agreement, since CorteX’s FDA submission is pending and cannot yet be sold commercially in America.

Medical division CEO Stuart Gall said: “We are excited to be taking this first step with IBEX". The partners will exhibit together at Chicago’s RSNA conference, offering an opportunity to engage hospitals, imaging centres and equipment manufacturers.

Longer term, I suspect Avingtrans will ultimately either sell or IPO the medical division. Separating it from the much bigger and highly profitable Advanced Engineering business (re unbundling opportunity).

Disclosure: Avingtrans is a Vox Markets client.